ストックスクリーナーアプリを入手
30.06
7.36%
2.06
前日終値:
$28.00
開ける：
$27.49
24時間の取引高:
295.83K
Relative Volume:
0.53
時価総額：
$1.86B
収益：
-
当期純損益:
$-209.84M
株価収益率:
-6.5777
EPS:
-4.57
ネットキャッシュフロー:
$-6.73M
1週間 パフォーマンス:
+3.66%
1か月 パフォーマンス:
+0.13%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$27.39
$30.35
1週間の範囲:
$26.52
$30.35
52週間の値動き範囲:
$16.50
$34.89
Damora Therapeutics Inc Stock (DMRA) Company Profile
Compare DMRA vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DMRA
Damora Therapeutics Inc
|
30.06 | 1.87B | 0 | -209.84M | -6.73M | -4.57 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Damora Therapeutics Inc Stock (DMRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-24 | 開始されました | RBC Capital Mkts | Outperform |
| 2026-03-25 | 開始されました | Evercore ISI | Outperform |
| 2026-02-17 | 開始されました | UBS | Buy |
| 2026-01-07 | 開始されました | Leerink Partners | Outperform |
| 2025-12-01 | 開始されました | Guggenheim | Buy |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2020-11-23 | 開始されました | BofA Securities | Buy |
| 2020-11-23 | 開始されました | Credit Suisse | Outperform |
| 2020-11-23 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Damora Therapeutics Inc (DMRA) 最新ニュース
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Trends and Sentiment 2026 - MarketBeat
Damora (DMRA) Results at a Glance: The Available Earnings Metric Delivers a Miss in the Current Update; Session Move: The Share Price Sheds 6.23% in Latest TradingEarnings Decline Risk - vinanet.vn
Damora Therapeutics (DMRA) Is Up 5.1% After Starting CLARITY-101 mutCALR Trial Has The Bull Case Changed? - simplywall.st
Damora Therapeutics (DMRA) Starts CLARITY 101 Trial With Valuation Still In Focus - Sahm
Damora Therapeutics (DMRA) Adds 1.01% as Bulls Defend Key Support ZoneVolatility Smirk - vinanet.vn
Damora Therapeutics (DMRA) Advances 1.01% to $31.04 as Biotech Sentiment SteadiesKAMA Signal - dars.gov.et
Damora Therapeutics Director Andrew Cheng Granted Stock Options for 30,350 Shares - Kalkine Media
Damora Therapeutics (DMRA) director awarded 30,350 stock options at $31.00 strike - Stock Titan
Damora Therapeutics (DMRA) files Form 3 for new director Andrew Cheng - Stock Titan
DMRA Q1 2026 Earnings: EPS Misses Estimates by 56.8% as Shares Rise 8%Fiscal Year Earnings - vinanet.vn
Equities Analysts Offer Predictions for DMRA Q3 Earnings - MarketBeat
Damora Therapeutics, Inc. SEC Filing (Aug 13, 2026) - Stock Titan
Damora Therapeutics: Competition Validates The Target While Its Portfolio Creates The Upside - Seeking Alpha
RBC Capital Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat
DMRA SWOT Analysis: Financial Strength and Growth Potential Reve - GuruFocus
Damora Therapeutics Q2 Results: Net Loss Widens To $31.2 Million - scanx.trade
Damora Therapeutics Q2 Results: EPS beats estimate, losses narrow - scanx.trade
Damora Therapeutics (NASDAQ: DMRA) resets $150M ATM after Cayman redomestication - Stock Titan
Damora Therapeutics, Inc. SEC Filing (Aug 10, 2026) - Stock Titan
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - The Manila Times
Damora Starts DMR-001 Trial With 100 mg Monthly Dose - Stock Titan
Damora Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Does CLARITY-101’s mutCALR Antibody Launch Change The Bull Case For Damora Therapeutics (DMRA)? - simplywall.st
DMRA Q1 2026 Earnings: Wider-than-Expected Loss Signals Rising Clinical-Stage Cost PressuresQuarterly Earnings - vinanet.vn
Damara (DMRA): Lori Firmani plans sale of 1,800 common shares via Maxim - Stock Titan
Damora Therapeutics, Inc. Common Stock (DMRA) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - marketbeat.com
Damora initiates phase 1 trial of mutCALR antibody therapy - Investing.com
Damora initiates phase 1 trial of mutCALR antibody therapy By Investing.com - Investing.com Australia
Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis - The Manila Times
Damora Begins Testing Antibody Designed for Monthly Doses - Stock Titan
Damora Therapeutics earnings on deck as rare blood cancer race heats up - Investing.com India
Damora Therapeutics grants 451,000 stock options to six new hires - scanx.trade
DMRA Q1 2026 Earnings: EPS Misses by 56.8% as Loss Widens, Shares SlipCore Business Growth - vinanet.vn
Damora Therapeutics (DMRA) Edges Higher at $29.37 as Traders Eye Key Resistance at $30.84Fade Trade - dars.gov.et
Wedbush Increases Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Price Target to $40.00 - MarketBeat
Damora Therapeutics, Inc. Common Stock (DMRA) to Post Earnings on Wednesday - MarketBeat
BlackRock (DMRA holder) reports 3.14M Damora Therapeutics shares in new ownership filing - Stock Titan
DMRA Initiates Coverage On Jefferies -- Rating Set to Buy, PT at $50 - GuruFocus
Jefferies Initiates Coverage on Damora Therapeutics With Buy Rating, $50 Price Target - marketscreener.com
H.C. Wainwright reiterates Damora Therapeutics stock rating on device advantage - Investing.com Canada
This Damora Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Jefferies initiates Damora Therapeutics stock with buy rating By Investing.com - Investing.com Canada
This Warner Bros Discovery Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday - Sahm
Damora Therapeutics (DMRA) Slips 1.2% as Stock Approaches Key Support at $27.38Institutional Sentiment - dars.gov.et
Damora Therapeutics, Inc. Revenue Breakdown – NASDAQ:DMRA - TradingView
Damora Therapeutics, Inc. Common Stock (DMRA) Institutional Ownership 2026 - MarketBeat
Damora Therapeutics (DMRA) AGM 2026 Summary - Quartr
Damora Therapeutics (DMRA) Proxy filing Summary - Quartr
symbol__ Stock Quote Price and Forecast - CNN
Damora Therapeutics Inc (DMRA) 財務データ
収益
当期純利益
現金流量
EPS
Damora Therapeutics Inc (DMRA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Winslow Garrett | General Counsel |
Jul 06 '26 |
Sale |
29.98 |
245 |
7,345 |
2,289 |
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):